Stock Events

Stock Events

Evaxion A/S 

$3.59
0
-$0.11-2.97% Friday 07:54

Statistics

Day High
3.6
Day Low
3.58
52W High
-
52W Low
-
Volume
210
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-316%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
6.69MRevenue
-21.13MNet Income

Analyst Ratings

$11.25Average Price Target
The highest estimate is 16.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVAX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a leader in mRNA technology, directly competing with Evaxion's focus on developing vaccines and treatments using similar technology.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes in the mRNA vaccine space, similar to Evaxion's approach to vaccine development, making them direct competitors.
Novavax
NVAX
Mkt Cap1.36B
Novavax is involved in the development of vaccines for infectious diseases, competing with Evaxion's infectious disease vaccine programs.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is focused on gene editing, a technology that can be seen as complementary or competitive to Evaxion's AI-driven approach to drug development.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another company working on CRISPR technology, potentially competing with Evaxion's efforts in genetic-based therapies.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the gene editing space, which could compete with Evaxion's technology in developing treatments for various diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a large pharmaceutical company with a broad portfolio that includes vaccines and treatments that could compete with Evaxion's products.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen Pharmaceuticals division, develops vaccines and therapeutics that could compete with Evaxion's pipeline.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, and influenza, competing with Evaxion's infectious disease focus.
Merck
MRK
Mkt Cap214.76B
Merck is a global healthcare company that develops vaccines and therapeutics, including for infectious diseases, competing with Evaxion's product pipeline.

About

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Show more...
CEO
ISIN
US29970R3030

Listings

XNAS
US
EVAX
BOATS
BOATS
EVAX.BOATS

0 Comments

Share your thoughts

FAQ

What is Evaxion A/S stock price today?▼
The current price of EVAX.BOATS is $3.59 USD — it has decreased by -2.97% in the past 24 hours. Watch Evaxion A/S stock price performance more closely on the chart.
What is Evaxion A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Evaxion A/S stocks are traded under the ticker EVAX.BOATS.
What is Evaxion A/S revenue for the last year?▼
Evaxion A/S revenue for the last year amounts to 6.69M USD.
What is Evaxion A/S net income for the last year?▼
EVAX.BOATS net income for the last year is -21.13M USD.
When did Evaxion A/S complete a stock split?▼
Evaxion A/S has not had any recent stock splits.